ERBB2 and neuroblastoma: One phase 2 open‐labelled clinical trial in the solid tumor domain is recruiting patients with HER2‐positive neuroblastoma to receive intracranial injections of HER2‐directed CAR NK‐92 cells carrying CD3ζ and CD28 signalling components (NCT03383978).